trending Market Intelligence /marketintelligence/en/news-insights/trending/kdojMHjeApZCw3GzCSxBdQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK's NICE backs Pfizer, AstraZeneca's Ibrance-Faslodex combo for breast cancer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UK's NICE backs Pfizer, AstraZeneca's Ibrance-Faslodex combo for breast cancer

The U.K. National Institute for Health and Care Excellence recommended a combination of Pfizer Inc.'s Ibrance and AstraZeneca PLC's Faslodex for use on the Cancer Drugs Fund to treat certain patients with breast cancer who have undergone hormone therapy.

The drug price watchdog previously approved Novartis AG's Kisqali and Eli Lilly and Co.'s Verzenio for patients with advanced breast cancer that are hormone receptor-positive and human epidermal growth factor receptor 2, or HER2, negative.

Ibrance, or palbociclib, belongs to a class of drugs called CDK4/6 inhibitors, which work by blocking a person's estrogen production, preventing the substance from stimulating the growth of certain cancers.

The Ibrance-Faslodex combination is another treatment option for up to 3,300 women who have had hormone therapy — treatments that add, block or remove hormones for cancer control instead of directly targeting cancer cells, according to NICE. These patients would otherwise receive a combination of Novartis' Afinitor, also called everolimus, and Pfizer's Aromasin, or exemestane.

NICE said its committee considers that the combination has the potential to be cost-effective despite uncertain estimates and recommended the use of the drug on the Cancer Drugs Fund to collect more evidence.

The combination is already available to National Health Service patients in England after the publication of NICE's draft recommendation in November 2019.

Ibrance was first approved in 2015 to treat women with breast cancer. The U.S. Food and Drug Administration expanded the approval in April 2019 to include men with a subtype of the disease. The FDA issued a warning in September 2019 that the drug may cause rare but severe inflammation.